PRMT6 Regulates RAS/RAF Binding and MEK/ERK-Mediated Cancer Stemness Activities in Hepatocellular Carcinoma through CRAF Methylation

Graphical Abstract

Highlights

- PRMT6 is downregulated in HCC and correlates negatively with aggressive HCC
- PRMT6 silencing drives cancer stemness in vitro and patient-derived organoids
- PRMT6 binds to CRAF, methylates it, and interferes with its RAS/RAF binding
- Methylation of CRAF regulates MEK/ERK-mediated cancer stemness in HCC

Authors

Lok Hei Chan, Lei Zhou, Kai Yu Ng, ..., Xin-Yuan Guan, Michael S.Y. Huen, Stephanie Ma

Correspondence

stefma@hku.hk

In Brief

RAS/RAF/MEK/ERK pathway signaling is known to be frequently activated in cancers, in which it regulates cell growth, malignant transformation, drug resistance, and stemness. Using hepatocellular carcinoma as a model system, Chan et al. describe a mechanism by which this oncogenic signaling pathway is regulated by PRMT6 at the post-translational level via arginine methylation.
PRMT6 Regulates RAS/RAF Binding and MEK/ERK-Mediated Cancer Stemness Activities in Hepatocellular Carcinoma through CRAF Methylation

Lok Hei Chan,1,11 Lei Zhou,1,11 Kai Yu Ng,1,11 Tin Lok Wong,1,11 Terence K. Lee,7 Rakesh Sharma,2 Jane H. Loong,1 Yick Pang Ching,1,3 Yun-Fei Yuan,8 Dan Xie,8 Chung Mau Lo,3,5 Kwan Man,3,5 Benedetta Artegaiani,9 Hans Clevers,9 Helen H. Yan,1 Suet Yi Loung,6 Stéphane Richard,10 Xin-Yuan Guan,3,4 Michael S.Y. Huen,1 and Stephanie Ma1,3,12,*

1School of Biomedical Sciences, University of Hong Kong, Pokfulam, Hong Kong, China
2Proteomics & Metabolomics Core Facility, Li Ka Shing Faculty of Medicine, University of Hong Kong, Pokfulam, Hong Kong, China
3State Key Laboratory for Liver Research, University of Hong Kong, Pokfulam, Hong Kong, China
4Department of Clinical Oncology, University of Hong Kong, Queen Mary Hospital, Pokfulam, Hong Kong, China
5Department of Surgery, University of Hong Kong, Queen Mary Hospital, Pokfulam, Hong Kong, China
6Department of Pathology, University of Hong Kong, Queen Mary Hospital, Pokfulam, Hong Kong, China
7Department of Applied Biology & Chemical Technology, Hong Kong Polytechnic University, Hong Kong, China
8State Key Laboratory of Oncology in Southern China, Sun Yat-Sen University Cancer Centre, Guangzhou, China
9Hubrecht Institute for Developmental Biology and Stem Cell Research, University Medical Centre Utrecht, Utrecht, the Netherlands
10Lady Davis Institute, Jewish General Hospital, and Departments of Oncology and Medicine, McGill University, Montreal, QC, Canada
11These authors contributed equally
12Lead Contact
*Correspondence: stefma@hku.hk
https://doi.org/10.1016/j.celrep.2018.09.053

SUMMARY

Arginine methylation is a post-translational modification that plays pivotal roles in signal transduction and gene transcription during cell fate determination. We found protein methyltransferase 6 (PRMT6) to be frequently downregulated in hepatocellular carcinoma (HCC) and its expression to negatively correlate with aggressive cancer features in HCC patients. Silencing of PRMT6 promoted the tumor-initiating, metastasis, and therapy resistance potential of HCC cell lines and patient-derived organoids. Consistently, loss of PRMT6 expression aggrivated liver tumorigenesis in a chemical-induced HCC PRMT6 knockout (PRMT6−/−) mouse model. Integrated transcriptome and protein-protein interaction studies revealed an enrichment of genes implicated in RAS signaling and showed that PRMT6 interacted with CRAF on arginine 100, which decreased its RAS binding potential and altered its downstream MEK/ERK signaling. Our work describes a critical repressive function for PRMT6 in maintenance of HCC cells by regulating RAS binding and MEK/ERK signaling via methylation of CRAF on arginine 100.

INTRODUCTION

Post-translational modifications lie at the heart of the fields of epigenetics and signal transduction. Arginine methylation is a common post-translational modification functioning as an epigenetic machinery of transcription and playing key roles in mRNA translation, cell signaling, and cell fate decision. In mammals, arginine methylation is carried out by protein arginine methyltransferases (PRMTs) (Bedford and Clarke, 2009; Blanc and Richard, 2017). Recent studies have defined physiological roles of PRMTs, linking them to diseases such as cancer and metabolic disorders. PRMT6 belongs to the type I PRMT enzyme family, responsible for catalyzing the asymmetric dimethylation of arginine (ADMA) residues on proteins (Blanc and Richard, 2017). It was initially identified to modify GAR motifs and subsequently found to target histones, although non-histone targets have also been described (Frankel et al., 2002; Guccione et al., 2007; Iberg et al., 2008; Hyllus et al., 2007; Di Lorenzo et al., 2014). The role of PRMT6 in normal and cancer cell remains controversial. It has been reported to function as both a transcriptional repressor and activator and be overexpressed and repressed in different tumor types. Reduced PRMT6 expression has been reported in melanoma (Limm et al., 2013), while over-expression of PRMT6 is detected in cancers of the bladder, lung, cervix, breast, and prostate (Almeida-Rios et al., 2016; Yoshimatsu et al., 2011). Importantly, studies on PRMT6 to date have only been focused on its function in the nucleus. The biological significance and the key target proteins of PRMT6 in human cancer remains elusive.

Hepatocellular carcinoma (HCC) remains one of the most prevalent and deadliest cancer types in the world. Resection and transplantation is remedial for early-stage HCC. Yet because most patients are diagnosed at an advanced stage, most HCCs are inoperable. Chemotherapy and molecular targeted therapies are available for advanced HCC patients, but their effects have shown only modest results. HCC tumors are heterogeneous and contain cells that sit at the apex of cellular hierarchies with stem-like properties. These HCC stem-like cells can self-renew, are resistant to conventional therapy, and can
contribute to tumor recurrence (Yamashita and Wang, 2013). Treatment of HCC with chemotherapy has been found to select for the outgrowth of therapy-resistant stem-like cancer cells that contribute to tumor recurrence and poor therapeutic outcome (Visvader and Lindeman, 2012). This underscores the need for a better understanding of the molecular mechanisms driving stemness in HCC cells in hope to discover features that may render HCC cells with stem-like properties more susceptible to selective therapeutic intervention.

RAF kinases are well-known oncoproteins that play a critical role in promoting cancer through activation of the MEK/ERK signaling cascade (Lavoie and Therrien, 2015). In recent years, MEK/ERK activation has been extensively reported to be essential for mediating the self-renewal capacity and drug-resistant properties of HCC cells, leading to poor patient survival. Activation of the RAS/RAF/MEK/ERK cascade is observed in 50%–100% of HCC tumors (Ito et al., 1998), yet activating mutations of RAS/RAF are infrequent, with downregulation of inhibitory regulators of the pathway being the more common alternative mechanism leading to activation of MEK/ERK. Although the presence of repressive elements in RAF has been long recognized, they cannot account for all MEK/ERK activations in HCC, while post-translational modifications other than phosphorylation that control RAF kinase activity remains elusive. A broader understanding of how negative regulatory effectors on this signaling pathway are deregulated in HCC is important for future development of anti-cancer strategies. Our present study uncovered the clinical significance and functional role of PRMT6 in mediating HCC stemness and dissected the molecular mechanism by which PRMT6 contributes to these effects via interaction and methylation of CRAF on arginine 100.

RESULTS

PRMT6 Is Weakly Expressed and Negatively Correlated with Aggressive Cancer Features in HCC Patients

We investigated PRMT6 mRNA expression in 77 primary HCC and matched non-tumor liver tissues using qPCR. PRMT6 downregulation of ≥2-fold was displayed in 55.8% (43 of 77) of the HCC specimens compared with non-tumor specimens (Figures 1A and 1B). Analysis of a publicly available dataset (The Cancer Genome Atlas [TCGA], Liver Cancer) also showed PRMT6 downregulation in HCC compared with normal liver samples (Figure 1C). These observations were further validated by immunohistochemistry (IHC) in a separate cohort consisting of 83 primary HCC and adjacent non-tumor tissue (Figures 1D and 1E), in which PRMT6 downregulation in HCC was...
significantly associated with older age (p = 0.025), presence of vascular invasion (p = 0.035), intraoperative rupture (p = 0.049), and a trend toward absent or incomplete tumor encapsulation (p = 0.053) (Table S1). Different PRMT6 antibodies were used for IHC, including one validated by the Human Protein Atlas, to provide further confidence to our work (Figure S1). Expression of PRMT6 was also tested in HCC cell lines for selecting cell lines for subsequent functional studies (Figure 1F).

PRMT6 Negatively Regulates Cancer and Stem Cell-like Properties in HCC
To determine the pathological role of PRMT6 in HCC, we ablated PRMT6 expression in BEL7402 with two distinct short hairpin RNAs (shRNAs) (933 and 956) and stably overexpressed PRMT6 in Huh7 and/or MHCC97L cells (Figures S2A–S2C). Knockdown of PRMT6 resulted in attenuated PRMT6 expression but not other members of the PRMT family, providing evidence that the effects observed are due solely to PRMT6 (Figure S2D). PRMT6 depletion led to potentiated ability of the cells to migrate, invade, and resist cisplatin, 5-fluorouracil, and sorafenib. Conversely, stably PRMT6 overexpression in Huh7 cells resulted in opposing effects (Figures 2A and 2B). We extended our studies in vivo, in which HCC cells with PRMT6 manipulated were injected subcutaneously or orthotopically into nude mice to determine the role of PRMT6 in HCC formation. Overexpression of PRMT6 resulted in a profound decrease in the ability of cells to initiate tumor growth, while knockdown of PRMT6 led to a marked induction (Figures 2C and 2D). We also examined the role of PRMT6 in HCC metastasis in vivo by orthotopic implantation of HCC cells into the livers of immunodeficient mice. Because BEL7402 and Huh7 cells are known to be unable to form metastases following intrahepatic injection, luciferase-labeled MHCC97L cells overexpressing empty vector (EV) or PRMT6 were used instead. Extrahepatic lung metastasis was monitored by ex vivo bioluminescence imaging, and metastasis was detected in four of six mice in the EV group, in contrast to only two of six mice in the PRMT6 overexpression group (Figure 2E), with a faster metastasis onset. Altered ability of the cells to metastasize was also evident by a decreased number of tumor nodules present in the lung of mice injected with PRMT6 overexpressing cells (Figure 2E).

PRMT6 negatively regulated not only aggressive cancer features but also stem-like properties of HCC. HCC cells with PRMT6 overexpressed displayed attenuated abilities to induce oncosphere formation in serial passages (Figure 3A), as well as reduced expression of CD133 HCC stem-like subpopulation (Figure 3B) and pluripotency markers SOX2 and NANOG (Figure 3C). Knockdown of PRMT6 resulted in an opposing trend (Figures 3A and 3C). Note expression of other liver cancer stem cell (CSC) markers such as CD24 and CD90 were not found to be altered following PRMT6 expression modulation (Figure S2F). To assess the degree to which PRMT6 supports growth and maintenance of CD133+ HCC stem-like cells, Huh7 cells overexpressing EV (PRMT6low) or PRMT6 (PRMT6high) were sorted into CD133+ and CD133− subsets and injected into NOD/SCID mice at limiting dilutions. Mice injected with CD133+PRMT6low cells showed increased tumor incidence, expedited tumor latency, and a higher frequency of tumor-initiating cells compared with other subgroups (Figure 3D). Self-renewal ability of cells was then examined by serial transplantation of primary xenografts into secondary mouse recipients. Single cells isolated from the four groups were resorted into CD133+ and CD133− subsets and injected at limiting dilutions. CD133+PRMT6low cells displayed further expedited tumor latency in their ability to reconstitute tumor formation in secondary transplants. Statistically, HCC cells with low PRMT6 showed a significantly worse tumor-free survival compared with HCC cells with high PRMT6 expression (CD133+ PRMT6low versus CD133+PRMT6high) in serial transplantations (Figure 3D).

The Catalytically Active Domain of PRMT6 Is Functionally Important in Contributing Augmented Cancer Stemness Properties in HCC
Lentiviral-based knockdown and overexpression of PRMT6 led to a concomitant respective decrease and increase of ADMA (Figure 4A), suggesting that the global arginine methyltransferase activity of these cells was altered. To examine whether PRMT6 confers altered cancer stemness properties in HCC through this enzymatic activity, we performed similar functional studies with wild-type PRMT6 or catalytic methyltransferase inactive mutant PRMT6VLD:KLA (Neault et al., 2012) overexpressed in BEL7402 HCC cells (Figure 4B). Ectopic overexpression of wild-type and catalytic inactive PRMT6 mutant displayed predominant cytoplasmic PRMT6 localization (Figure S3). Functionally, wild-type PRMT6 overexpression conferred the ability of HCC cells to diminish migration, invasion, and oncosphere formation (Figures 4C–4E). Furthermore, it led to attenuated ability of the cells to resist cisplatin, 5-fluorouracil, and sorafenib as well as a reduced expression of SOX2 (Figures 4G–4G). Overexpression of wild-type PRMT6 also resulted in a decrease in the ability of the cells to initiate tumors in vivo (Figure 4H). In contrast, a catalytic methyltransferase inactive mutant of PRMT6 was unable to confer such functional phenotype.

PRMT6 Interacts Directly with CRAF
Contrary to what is reported in the literature for other tumor types, we found modulation of PRMT6 to not play a very significant or consistent role in H3R2 methylation, at least in the context of HCC, as evidenced by both H3R2me2a expression and chromatin immunoprecipitation (ChIP)-qPCR experiments on promoter regions of p21, p27, and p57, previously reported to be regulated by H3R2me2a, coupled with expression analysis of p21, p27, and p57 extracted from our microarray data (Figure S4). More importantly, PRMT6 is predominantly expressed in the cytoplasm of HCC cells (Figure S5). To ensure that our observation was HCC specific, we performed the same immunofluorescence experiment using two PRMT6 antibodies and with MCF7 breast cancer cells, which have previously been reported to express only nuclear PRMT6 (Hetius et al., 2007), as
a positive control, with findings in support of our hypothesis (Figure S5). To elucidate the underlying mechanism of PRMT6 in the regulation of HCC stem-like cells, we used an integrative approach whereby we sought to identify both downstream altered genes and potential binding partners of PRMT6, hoping to identify members of the pathway that are regulated via arginine methylation. mRNA profiling of HCC cells with or without PRMT6 stably suppressed identified significantly deregulated genes that closely associated with RAS signaling and aggressive cancer phenotypes, including epithelial-mesenchymal transition (Figures 5A and 5F; Table S2). Tandem affinity purification coupled with mass spectrometry (TAP-MS) analysis of PRMT6 immunoprecipitates identified a list of PRMT6-interacting proteins. Through integrating mRNA profiling and TAP-MS analysis,
we shortlisted 11 RAS signaling-related proteins that potentially bind to PRMT6, including RAF1/CRAF (Table S3). Downstream signaling of CRAF, namely, MEK/ERK, has previously been shown by us and others to promote stem cell-like properties in HCC, and thus we hypothesized that PRMT6 regulates HCC stem-like cell via binding to CRAF and altering downstream MEK/ERK signaling. To test our hypothesis, we first confirmed the interaction between PRMT6 and CRAF by reciprocal immunoprecipitations in 293T and HCC cells, using both tagged and endogenous proteins (Figure 5B). Following confirmation of their binding, we then examined for the presence of PRMT6-mediated enzymatic methylation of CRAF by in vivo methylation assay. Levels of ADMA were drastically increased when PRMT6 plasmid was co-transfected relative to EV control (Figure 5C, left). To further provide direct evidence in support of CRAF as a specific PRMT6 substrate, in vitro methylation assay was then carried out, alongside a glycine-arginine-rich (GAR) sequence as a positive control. In the presence of PRMT6, methylation of CRAF was dramatically potentiated (Figure 5C, middle and right).

PRMT6 Methylates CRAF on Arginine 100 Residue
An in silico analysis of the CRAF protein sequence by PMeS prediction revealed seven arginine residues that could be potentially methylated (Table S4). To identify which arginine residues are methylated by PRMT6, we created full-length and multiple truncated mutants of CRAF (Figure 5D). When CRAF full-length (FL) and truncated mutants (D1–D3) were co-transfected with PRMT6 into 293T cells for in vivo methylation assay, ADMA at the predicted size (red arrows) could be detected in FL CRAF as well as D1 and D3 truncated CRAF, where arginine residues 89 and 100 are present. In contrast, the predicted ADMA band could not be detected in D2 truncated CRAF, where arginine 89 and 100 residues are deleted (Figure 5E, white arrow). These observations indicated that arginine 89 and 100 in CRAF were the potential targets of PRMT6.

In vivo and in vitro methylation assays using site-directed R89K and R100K CRAF mutants showed that only R100 was specifically methylated by PRMT6 (Figure 5F). This was further confirmed by in vitro methylation assays using peptide overlying nine amino acids around R100 residue (CAFVRLHHE) or with R → K substitution (CAFVKLHHE),
showing methyl group incorporation in R100 peptide only (Figure 5G). On further analysis, we also found PRMT6 to similarly bind to other RAF family members that show high homology to CRAF, including ARAF and BRAF. Arginine residues were also predicted on ARAF and BRAF (Table S4), with R100 consistently corresponding to the 45th amino acid residue within the RAS binding domain (RBD) across all three human RAF proteins and locating within a highly conserved sequence motif consisting of six amino acids (Tables S5 and S6), suggesting the critical role of this arginine residue. The data serve as proof of concept that PRMT6 may potentially methylate ARAF and BRAF at the same arginine residue to elicit similar downstream effects, as in CRAF.

**PRMT6 Methylation of CRAF at Arginine 100 Interferes with RAS/RAF Binding Domain and Inhibits MEK/ERK-Related Kinase Activity**

As evidenced by western blot and kinase activity assays, knockdown of PRMT6 led to heightened MEK/ERK signaling, while
Figure 5. PRMT6 Interacts Directly with CRAF and Methylates It on Arginine 100 Residue

(A) Gene set enrichment analysis (GSEA) identified an enrichment of RAS signaling in PRMT6 silenced cells.

(B) Co-immunoprecipitation analysis for validation of CRAF as a PRMT6 interacting protein partner in 293T cells expressing SFB-tagged PRMT6, 293T cells expressing SFB-tagged CRAF, BEL7402 cells expressing SFB-tagged PRMT6, and BEL7402 expressing endogenous PRMT6.

(C) Left: western blot analysis for PRMT6-mediated incorporation of asymmetric arginine dimethylation in CRAF. Middle: western blot analysis of in vitro methylation assay of CRAF. Right: GAR (glycine-arginine-rich) sequence positive control in the in vitro methylation assay.

(D) Schematic diagram illustrating of full-length (FL) and deletion mutations of CRAF used in this study. CRD, cysteine-rich domain; RBD, Ras binding domain.

(E) Mapping of protein domain in CRAF methylated by PRMT6 through in vivo methylation assay. Red arrows indicate ADMA bands at the predicted size. White arrow indicates loss of ADMA band at the predicted size in D2 CRAF truncation mutant. Yellow arrows indicate successful FLAG pull-down.

(F) Left: levels of ADMA in WT and site-directed mutants of CRAF. Right: in vitro methylation assay of CRAF R100K mutant versus WT.

(G) Left: in vitro methylation assay with immunoprecipitated PRMT6 from 293T cells stably transfected with SFB-PRMT6. Assay was performed by adding no peptide, CAVFRLLHE peptide, or CAVFKLLHE mutant peptide. Right: fragmentation spectrum of the methylated peptide identified by liquid chromatography/tandem mass spectrometry (LC-MS/MS). m/z, mass/charge ratio. ***p < 0.001.

Endo, endogenous; Exo, exogenous; KD, knockdown; mut, mutant; NTC, non-target control; WT, wild-type. Data are representative of two or more independent experiments. Bars and error represent mean ± SD of replicate measurements.
overexpression of PRMT6 resulted in an opposing effect (Figure 6). To substantiate the importance of the MEK/ERK pathway in PRMT6-mediated HCC, we performed rescue experiments using an MEK-specific inhibitor, U0126, as well as by shERK1/2 knockdown (Figures 6B, 6C, and S7). U0126 and shERK1/2 suppressed the oncogenic properties conferred by PRMT6 knockdown, as evidenced by the diminished abilities of HCC cells to migrate, invade, form oncospheres, and resist sorafenib treatment (Figures 6B, 6C, and S7). Most important, overexpression of CRAF with R100K mutation in PRMT6 expressing BEL7402 cells led to a heightened p-ERK1/2 signal and ERK kinase activity with c-Jun as a substrate compared with wild-type CRAF (Figure 6D), demonstrating the significance of CRAF R100 residue in regulating MEK/ERK signaling. Co-immunoprecipitation of CRAF showed that shPRMT6 promoted the RAS/RAF binding, which could be inhibited by restoring PRMT6 expression.

Figure 6. PRMT6 Methylation of CRAF at Arginine 100 Interferes with RAS/RAF Binding Domain and Inhibits MEK/ERK-Related Kinase Activity
(A) CRAF kinase assay, western blot analysis for expression of phosphorylated and total MEK1/2, phosphorylated and total ERK1/2 and ERK kinase assay in BEL7402 and Huh7 cells with or without PRMT6 expression modulated.
(B) Representative images and quantification of number of cells that migrated, invaded, and formed oncospheres in BEL7402 cells expressing NTC or shPRMT6 clone 956 that were treated with control or MEK inhibitor U0126. ***p < 0.001. Scale bar, 100 μm.
(C) Percentage of annexin V-PI-positive cells in BEL7402 cells expressing NTC or shPRMT6 clone 956 that were treated with control or MEK inhibitor U0126, following sorafenib treatment.
(D) Western blot analysis for expression of CRAF, phosphorylated and total ERK1/2, as well as ERK kinase assay in BEL7402 cells with EV control, CRAF WT, or CRAF R100K overexpressed.
(E and F) Western blot analysis for the co-immunoprecipitation of CRAF and RAS in BEL7402 cells (E) with or without PRMT6 expression modulated and (F) with CRAF WT or R100K mutant.
(G) In vitro methylation assay of CRAF WT and R100K mutant followed by RAS binding assay with immunoprecipitated MBP-RAS.
EV, empty vector control; NTC, non-target control; OE, overexpression; WT, wild-type. Data are representative of two or more independent experiments. Bars and error represent mean ± SD of replicate measurements.
The observation that binding between RAS and CRAF with R100K mutation was not affected by shPRMT6 also confirmed the importance of R100 residue methylation (Figure 6F). To show that PRMT6-mediated methylation regulates RAS/RAF binding, GST-CRAF with or without in vitro methylation was subsequently incubated with MBP-RAS for RAS binding assay. Upon PRMT6 in vitro methylation, RAS binding affinity was diminished in CRAF wild-type (WT) but not in CRAF R100K mutant (Figure 6G).

**Loss of PRMT6 Expression Aggravates Liver Tumorigenesis in a DEN+CCL4 HCC-Induced PRMT6 Knockout Mouse Model**

Next, we extended our studies with PRMT6 knockout (PRMT6−/−) mice (Neault et al., 2012). WT C57BL/6J and PRMT6−/− mice were subjected to DEN+CCL4 treatment, for induction of a fibrosis/inflammation-associated HCC that closely mimics the disease in human. PRMT6−/− mice developed bigger HCC tumors than WT mice and a trend toward higher liver over body weight in PRMT6−/− mice (Figures 7A and 7B). H&E staining revealed larger areas of tumors in PRMT6−/− mice compared with controls, while IHC also showed absence of PRMT6, concomitant with stronger expression of pERK1/2 in the PRMT6−/− mice compared with WT mice (Figure 7C).

**PRMT6-Dependent CRAF/ERK Signaling Regulates HCC Stemness as Demonstrated in Patient-Derived Non-tumor Liver and HCC Organoids**

To examine whether our hypothesis of a PRMT6-dependent CRAF/ERK signaling regulation of HCC cells could be further...
extended in a setting that more closely mimics the real clinical situation, we established non-tumor liver and HCC patient-derived three-dimensional (3D) organoids, with or without PRMT6 stably altered (Figure 7D). Note that our organoids have been thoroughly characterized at both molecular and phenotypic levels, with comparison made against the original non-tumor liver and HCC tissue samples (unpublished data). Knockdown of PRMT6 in non-tumor liver organoids significantly enhanced the abilities of the cells to resist both chemo- and molecular-targeted drugs, while overexpression of PRMT6 in HCC organoids attenuated the cells ability to migrate, invade, and form oncospheres (Figures 7E and 7F). Consistently, alteration in expression of CD133, NANOG, SOX2, and p-ERK1/2 was also observed (Figure 7D).

**DISCUSSION**

Arginine methylation is a post-translational modification as common as phosphorylation and ubiquitination (Larsen et al., 2016). The methylation of arginine residues is catalyzed primarily by PRMT enzymes, which includes PRMT6. Previous studies found PRMT6 to be predominantly nuclear and methylates arginine- and glycine-rich (RGG/RG) motifs, though it has also been shown to methylate arginines neighboring charged residues, as observed with HIV Tat (Boulanger et al., 2005). PRMT6-mediated methylation is generally associated with transcriptional repression by generating H3R2me2a (Guccione et al., 2007; Iberg et al., 2008; Hyltitus et al., 2007; Di Lorenzo et al., 2014), although it has also been reported that PRMT6 functions as a co-activator of nuclear receptors (Harrison et al., 2019). PRMT6-mediated histone methylation also regulates poised chromatin to maintain the balance between pluripotency and differentiation (Lee et al., 2012). In the normal liver, PRMT6 promotes fasting-induced transcriptional activation of gluconeogenesis involving CRTC2 (Han et al., 2014). Earlier studies have suggested the regulatory function of PRMT6 in cellular proliferation, senescence, and cell cycle progression (Kleinschmidt et al., 2012; Phalke et al., 2012; Stein et al., 2012), while one very recent study reported on the role of PRMT6 in regulating DNA methylation and contributing to global DNA hypomethylation in cancers of the breast, prostate, colon, lung, nerve, and bone (Veeland et al., 2017). Yet the disease-associated expression and function of PRMT6 in HCC have remained unclear. Our present study finds PRMT6 to play a critical role in negatively regulating the maintenance of stemness feature of HCC cells. It is interesting to also note that, consistent with the study by Veeland et al. (2017), our pilot data also suggest that arginine methyltransferase activity of PRMT6 results in DNA hypomethylation in HCC cells, as evident by 5mc immunofluorescence staining. Specifically, global DNA hypomethylation was observed in cells overexpressing WT PRMT6 but not the catalytic inactive PRMT6 mutant (data not shown). However, whether this observed methylation change is dependent on H3R2me2a remains to be elucidated.

The upstream regulator of PRMT6 has not been defined. PRMT6 lies on chromosome 1p13.3, which has previously been reported to be frequently detected in HCC (Guan et al., 2000). Thus, we also did some preliminary analysis on data extracted from TCGA Liver Hepatocellular Carcinoma (LIHC) to examine if gene copy number loss or deletion contributes to the frequent downregulation of PRMT6 in HCC. We found PRMT6 gene copy number loss or deletion to be detected in 23.5% of 370 HCC samples and that the loss was positively correlated with decreased PRMT6 mRNA expression (data not shown). In addition, we also identified a CpG island in the promoter region of PRMT6 and also carried out pilot studies to test if 5-aza-2’-deoxycytidine (5-aza) and trichostatin A (TSA) combination treatment would lead to re-expression of PRMT6 in low-PRMT6-expressing HCC cells. Treatment with 5-aza and TSA resulted in only a slight 2-fold to 3-fold re-expression of PRMT6 (data not shown). Our data on the underlying mechanisms contributing to PRMT6 downregulation in HCC remain inconclusive, and further study is warranted. Whether PRMT6 is regulated by microRNAs (miRNAs) or other regulatory proteins can also be further explored.

PRMT6-mediated H3R2me2a of promoter DNA leads to epigenetic silencing of transcription of the cell cycle inhibitor p21 as well as the angiogenic inhibitor TSP1 (Phalke et al., 2012; Michaud-Levesque and Richard, 2009; Nakakido et al., 2015; Kim et al., 2013). It remains to be elucidated whether PRMT6 act as a chromatin modifier in HCC. Our pilot data are at the moment inconclusive, as evidenced by enhanced methylation at the promoter regions of p21, p27, and p57 by H3R2me2a, despite inconsistent p21, p27, and p57 expression change and H3R2me2a expression being unaltered when PRMT6 is modulated (Figure S4). But more interestingly, we observed a predominant cytoplasmic localization of PRMT6 in normal liver and HCC cells, rather than its well-recognized nuclear localization. This observation was validated with two PRMT6 antibodies, including one that is validated by the Human Protein Atlas. Why PRMT6 is predominantly localized in the cytoplasm of liver and HCC cells remains to be answered, but in the past, a number of PRMTs, such as PRMT1 and PRMT5, have also been found to be capable of shuttling between the nucleus and cytoplasm (Herrmann et al., 2005; Herrmann and Fackelmayer, 2009; Gu et al., 2012). For instance, presence of nuclear exclusion signals (NESs) is found responsible for the cytoplasmic localization of PRMT5 in prostate pre-malignant and cancer tissues (Gu et al., 2012). It will be interesting to explore whether liver and HCC cells also contain such NES in the PRMT6 protein.

Although non-histone proteins, including GPS2, CRTC2, Tat, HMGA1a, and PRMT6 itself, are known substrates of PRMT6 (Boulanger et al., 2005; Han et al., 2014; Singhroy et al., 2013; Huang et al., 2015), cytoplasmic proteins specifically methylated by PRMT6 have not been reported. Through an integrative approach, adopting both transcriptome and protein-protein interaction studies, CRAF was identified as one of the cytoplasmic interacting partners of PRMT6. We went on to validate CRAF as a functional substrate of PRMT6 and identified R100 as the specific arginine residue on CRAF targeted by PRMT6. Methylation of CRAF on arginine 100 in the RBD would result in its altered RAS binding potential and thus modulation of the downstream MEK/ERK signaling cascade. Collectively, we found PRMT6 downregulation in HCC to mediate cancer stemness properties via decreased interaction with CRAF and thus reduced methylation on CRAF arginine 100, thereby resulting
in its altered RAS binding potential and subsequent activation of downstream MEK/ERK signaling.

Targeting MEK/ERK signaling and in vivo target gene activation of PRMT6 expression in HCC represents a promising anti-cancer stemness therapeutic strategy. In fact, there are a number of MEK/ERK inhibitors available on the market that are either approved for use in patients or under clinical evaluation, including the U.S. Food and Drug Administration (FDA)-approved MEK inhibitors trametinib (GSK1120212) and cobimetinib (GDC-0973, XL518) and MEK/ERK inhibitors in clinical trials, including binimetinib (MEK162), selumetinib, PD-325901, SCH772984, and others. There are now ample data to show that patients respond only partially to single-drug treatments against the MEK/ERK pathways and that MEK/ERK inhibitors would be best if given in combination with other drugs, instead of as a single agent. Our present study revealed that the downregulation of PRMT6 in HCC cells might subject cells to confer cancer and stemness features by activation of MEK/ERK signaling, thus promoting tumor-initiating and therapy resistance in HCC. These results suggest that it may be therapeutically relevant to consider methods to enhance PRMT6 expression in HCC, in combination with use of MEK/ERK inhibitors. In a recent study, Liao et al. (2017) elegantly reported a robust system for in vivo activation of endogenous target genes through trans-epigenetic remodeling. The system relies on recruitment of Cas9 and transcriptional activation complexes to target loci by modified single-guide RNAs; and as a proof of concept, they used the technology to treat mouse models of diabetes, muscular dystrophy, and acute kidney disease (Liao et al., 2017). This tool can be considered for use in PRMT6 gene activation in vivo in HCC patients and as a combination treatment along with use of MEK/ERK inhibitors for anti-cancer stemness targeting in HCC.

STAR METHODS

Details methods are provided in the online version of this paper and include the following:

- Key Resources Table
- Contact for Reagents and Resource Sharing
- Experimental Model and Subject Details
  - Cell lines and organoid cultures
  - Archived patient samples
  - Animal studies
- Methods Details
  - Reagents, kits and plasmids
  - Flow cytometry and cell sorting
  - Gene expression profiling
  - Agilent microarray profiling
  - Quantitative real-time PCR
  - Western blot and co-immunoprecipitation
  - Lentiviral production and cell transduction
  - CRISPR/Cas9 knockout
  - Immunohistochemistry
  - Immunofluorescence
  - Oncosphere-forming and self-renewal assay
  - Cell motility and invasion assays
  - Annexin V apoptosis assay
  - Cell viability assay
  - Tandem affinity purification – mass spectrometry
  - Methylation assays
  - Liquid chromatography–mass spectrometry analysis
  - In vitro RAS binding assay
  - ChiP-qPCR
- Quantification and Statistical Analysis
- Data and Software Availability

Supplemental Information

Supplemental Information includes seven figures and seven tables and can be found with this article online at https://doi.org/10.1016/j.celrep.2018.09.053.

Acknowledgments

This project is supported in part by grants from the Research Grants Council of Hong Kong – General Research Fund (17143516), Collaborative Research Fund (C7027-14G), and Theme Based Research Scheme (T12-710/16-R), as well as an Innovation Award from the Croucher Foundation. We thank the Faculty Core Facility and Proteomics & Metabolomics Core Facility (The University of Hong Kong) for providing and maintaining the equipment and technical support needed for flow cytometry analysis and cell sorting, animal imaging, confocal microscopy, and mass spectrometry.

Author Contributions

L.H.C. and S.M. conceived the project. L.H.C., L.Z., K.Y.N., and T.L.W. performed the research and analyzed and interpreted the data. T.K.L., Y.Y.G., M.P.C., and M.S.Y.H. provided plasmids and reagents. T.K.L. provided critical scientific input. R.S. performed mass spectrometry experiments. J.H.L. helped with organoid experiments. Y.F.Y., D.X., C.M.L., and K.M. obtained patient consent and provided the clinical samples and patient information. B.A., H.C., H.H.Y., and S.Y.L. provided expertise and reagents for liver organoid culture. S.R. provided PRMT6 WT and catalytically inactive mutant plasmids, PRMT6 knockout mice, as well as expertise on PRMT studies. M.S.Y.H. provided expertise and reagents for tandem affinity purification/mass spectrometry studies and assisted in data analysis. L.H.C., L.Z., K.Y.N., T.L.W., and S.M. wrote the manuscript. S.M. analyzed and interpreted the data, supervised the project, and provided funding for this study.

Declaration of Interests

The authors declare no competing interests.

Received: April 26, 2018
Revised: July 26, 2018
Accepted: September 16, 2018
Published: October 16, 2018

References


## STAR METHODS

### KEY RESOURCES TABLE

<table>
<thead>
<tr>
<th>REAGENT or RESOURCE</th>
<th>SOURCE</th>
<th>IDENTIFIER</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antibodies</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PE-conjugated anti-human CD133 (FACS)</td>
<td>Miltenyi Biotec</td>
<td>Cat No. 130-080-901; RRID: AB_244348</td>
</tr>
<tr>
<td>FITC-conjugated anti-human CD24 (FACS)</td>
<td>BD Biosciences</td>
<td>Cat No. 555427; RRID: AB_395821</td>
</tr>
<tr>
<td>FITC-conjugated anti-human CD90 (FACS)</td>
<td>Miltenyi Biotec</td>
<td>Cat No. 130-097-930; RRID: AB_2660947</td>
</tr>
<tr>
<td>Anti-human/mouse PRMT6 (WB, IHC and IF)</td>
<td>Abcam</td>
<td>Cat No. ab47244; RRID: AB_2284473</td>
</tr>
<tr>
<td>Anti-human CD133 (WB)</td>
<td>Miltenyi Biotec</td>
<td>Cat No. 130-092-395; RRID: AB_615061</td>
</tr>
<tr>
<td>Anti-human ADMA</td>
<td>Cell Signaling Technology</td>
<td>Cat No. 13522; RRID: AB_2665370</td>
</tr>
<tr>
<td>Anti-human SOX2</td>
<td>Abcam</td>
<td>Cat No. ab97959; RRID: AB_2341193</td>
</tr>
<tr>
<td>Anti-human NANOG</td>
<td>Cell Signaling Technology</td>
<td>Cat No. 3580; RRID: AB_2150399</td>
</tr>
<tr>
<td>Anti-human H3R2me2a</td>
<td>Millipore</td>
<td>Cat No. 07-585; RRID: AB_310733</td>
</tr>
<tr>
<td>Anti-human FLAG</td>
<td>Sigma Aldrich</td>
<td>Cat No. F3165; RRID: AB_259529</td>
</tr>
<tr>
<td>Anti-human p-CRAF (S338)</td>
<td>Cell Signaling Technology</td>
<td>Cat No. 9427; RRID: AB_2067317</td>
</tr>
<tr>
<td>Anti-human ARAF</td>
<td>Cell Signaling Technology</td>
<td>Cat No. 12552; RRID: AB_2728706</td>
</tr>
<tr>
<td>Anti-human BRAF</td>
<td>Cell Signaling Technology</td>
<td>Cat No. 9433; RRID: AB_2593954</td>
</tr>
<tr>
<td>Anti-human p-ERK1/2</td>
<td>Cell Signaling Technology</td>
<td>Cat No. 9101; RRID: AB_331646</td>
</tr>
<tr>
<td>Anti-human ERK1/2 (for WB and ERK kinase assay)</td>
<td>Cell Signaling Technology</td>
<td>Cat No. 9102; RRID: AB_330744</td>
</tr>
<tr>
<td>Anti-human p-MEK1/2 (S217/221)</td>
<td>Cell Signaling Technology</td>
<td>Cat No. 9154; RRID: AB_2138017</td>
</tr>
<tr>
<td>Anti-human MEK1/2</td>
<td>Cell Signaling Technology</td>
<td>Cat No. 9122; RRID: AB_823567</td>
</tr>
<tr>
<td>Anti-human RAS</td>
<td>Calbiochem</td>
<td>Cat No. OP01L; RRID: AB_565094</td>
</tr>
<tr>
<td>Anti-human Histone H3</td>
<td>Abcam</td>
<td>Cat No. ab24834; RRID: AB_470335</td>
</tr>
<tr>
<td>Anti-human β-actin</td>
<td>Sigma Aldrich</td>
<td>Cat No. A5316; RRID: AB_476743</td>
</tr>
<tr>
<td>Anti-human PRMT6 (Co-IP)</td>
<td>Bethyl Laboratories</td>
<td>Cat No. A300-928A; RRID: AB_661910</td>
</tr>
<tr>
<td>Rabbit IgG control (Co-IP)</td>
<td>Santa Cruz</td>
<td>Cat No. sc-2027; RRID: AB_737197</td>
</tr>
<tr>
<td>Anti-human PRMT6 (IHC and IF)</td>
<td>Atlas Antibodies</td>
<td>Cat No. HPA059424; RRID: AB_2684012</td>
</tr>
<tr>
<td>Anti-human SOX2 (for IHC)</td>
<td>R&amp;D Systems</td>
<td>Cat No. MAB2018; RRID: AB_358009</td>
</tr>
<tr>
<td>Anti-human p-ERK1/2 (for IHC)</td>
<td>Abcam</td>
<td>Cat No. ab50011; RRID: AB_1603684</td>
</tr>
<tr>
<td>Anti-human H3 (asymmetric di methyl R2)</td>
<td>Abcam</td>
<td>Cat No. ab175007</td>
</tr>
<tr>
<td>Anti-human CRAF (for CRAF kinase assay)</td>
<td>Millipore</td>
<td>Cat No. 07-396; RRID: AB_310580</td>
</tr>
<tr>
<td>Anti-human p53</td>
<td>Cell Signaling Technology</td>
<td>Cat No. 9282; RRID: AB_10693944</td>
</tr>
</tbody>
</table>

### Bacterial and Virus Strains

<table>
<thead>
<tr>
<th>REAGENT or RESOURCE</th>
<th>SOURCE</th>
<th>IDENTIFIER</th>
</tr>
</thead>
<tbody>
<tr>
<td>BL21(DE3) competent E.coli</td>
<td>New England Biolabs</td>
<td>Cat No. C25271</td>
</tr>
<tr>
<td>DH5α competent E.coli</td>
<td>Invitrogen</td>
<td>Cat No. 18260017</td>
</tr>
</tbody>
</table>

### Biological Samples

<table>
<thead>
<tr>
<th>REAGENT or RESOURCE</th>
<th>SOURCE</th>
<th>IDENTIFIER</th>
</tr>
</thead>
<tbody>
<tr>
<td>HCC and distal adjacent non-tumor liver tissues</td>
<td>Queen Mary Hospital (Hong Kong)</td>
<td>N/A</td>
</tr>
<tr>
<td>Human and distal adjacent non-tumor liver tissues</td>
<td>Sun Yat-Sen University Cancer Center (China)</td>
<td>N/A</td>
</tr>
</tbody>
</table>

### Chemicals, Peptides, and Recombinant Proteins

<table>
<thead>
<tr>
<th>REAGENT or RESOURCE</th>
<th>SOURCE</th>
<th>IDENTIFIER</th>
</tr>
</thead>
<tbody>
<tr>
<td>MEK inhibitor U0126</td>
<td>Cell Signaling Technology</td>
<td>Cat No. 9903</td>
</tr>
<tr>
<td>Unmodified CRAF R100 peptide (CAVFRLLHE)</td>
<td>GenScript</td>
<td>N/A</td>
</tr>
<tr>
<td>Modified CRAF R100K peptide (CAVFKLHE)</td>
<td>GenScript</td>
<td>N/A</td>
</tr>
</tbody>
</table>

### Critical Commercial Assays

<table>
<thead>
<tr>
<th>REAGENT or RESOURCE</th>
<th>SOURCE</th>
<th>IDENTIFIER</th>
</tr>
</thead>
<tbody>
<tr>
<td>ERK kinase assay (KinaseSTAR JNK assay kit)</td>
<td>BioVision</td>
<td>Cat No. K431-40</td>
</tr>
<tr>
<td>CRAF kinase assay</td>
<td>Millipore (Upstate)</td>
<td>Cat No. 17-360</td>
</tr>
<tr>
<td>PrimeSTAR GXL kit</td>
<td>Takara</td>
<td>Cat No. R050B</td>
</tr>
</tbody>
</table>

(Continued on next page)
### Deposited Data

<table>
<thead>
<tr>
<th>Data Type</th>
<th>Source</th>
<th>Identifier</th>
</tr>
</thead>
<tbody>
<tr>
<td>cDNA microarray (NTC control versus PRMT6 KD)</td>
<td>GEO, NCBI</td>
<td>GSE97931</td>
</tr>
</tbody>
</table>

### Experimental Models: Cell Lines

<table>
<thead>
<tr>
<th>Cell Line</th>
<th>Source</th>
<th>Identifier</th>
</tr>
</thead>
<tbody>
<tr>
<td>Human HCC cell line SNU182</td>
<td>ATCC</td>
<td>ATCC CRL-2235</td>
</tr>
<tr>
<td>Human HCC cell line HepG2</td>
<td>ATCC</td>
<td>ATCC HB8065</td>
</tr>
<tr>
<td>Human HCC cell line PLC8024</td>
<td>Institute of Virology, Chinese Academy of Sciences (China)</td>
<td>N/A</td>
</tr>
<tr>
<td>Human HCC cell line BEL7402</td>
<td>Shanghai Institute of Cell Biology, Chinese Academy of Sciences (China)</td>
<td>N/A</td>
</tr>
<tr>
<td>Human HCC cell line Huh7</td>
<td>JCRB Cell Bank</td>
<td>JCRB0403</td>
</tr>
<tr>
<td>Human HCC cell line MHCC97L</td>
<td>Liver Cancer Institute, Fudan University (China)</td>
<td>N/A</td>
</tr>
<tr>
<td>Human 293FT</td>
<td>Invitrogen</td>
<td>R70007</td>
</tr>
<tr>
<td>Human 293T</td>
<td>ATCC</td>
<td>ATCC CRL-3216</td>
</tr>
<tr>
<td>Human 293T/17</td>
<td>ATCC</td>
<td>ATCC CRL-11268</td>
</tr>
</tbody>
</table>

### Experimental Models: Organisms/Strains

<table>
<thead>
<tr>
<th>Organism/Strain</th>
<th>Source</th>
<th>Identifier</th>
</tr>
</thead>
<tbody>
<tr>
<td>PRMT6⁻/⁻ mice</td>
<td>Provided by Dr. Stéphane Richard (McGill University) (Neault et al., 2012)</td>
<td>N/A</td>
</tr>
<tr>
<td>C57BL/6J mice</td>
<td>Laboratory Animal Unit, University of Hong Kong</td>
<td>N/A</td>
</tr>
<tr>
<td>BALB/C nude mice</td>
<td>Laboratory Animal Unit, University of Hong Kong</td>
<td>N/A</td>
</tr>
<tr>
<td>NOD/SCID mice</td>
<td>Laboratory Animal Unit, University of Hong Kong</td>
<td>N/A</td>
</tr>
</tbody>
</table>

### Oligonucleotides

<table>
<thead>
<tr>
<th>Primers Description</th>
<th>Table</th>
<th>N/A</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primers for sub-cloning of WT PRMT6 and catalytically inactive PRMT6 mutant into pDONR201</td>
<td>S7</td>
<td></td>
</tr>
<tr>
<td>Primers for sub-cloning of FL and truncated mutants of CRAF into pDONR201</td>
<td>S7</td>
<td></td>
</tr>
<tr>
<td>Primers for sub-cloning of RAS into pDONR201</td>
<td>S7</td>
<td></td>
</tr>
<tr>
<td>Primers for construction of site-directed mutants of CRAF (R89K and R100K)</td>
<td>S7</td>
<td></td>
</tr>
<tr>
<td>Primers for cloning of PRMT6 knockouts</td>
<td>S7</td>
<td></td>
</tr>
<tr>
<td>PRMT6 qPCR primers</td>
<td>S7</td>
<td></td>
</tr>
<tr>
<td>p21 qPCR primers</td>
<td>S7</td>
<td></td>
</tr>
<tr>
<td>p27 qPCR primers</td>
<td>S7</td>
<td></td>
</tr>
<tr>
<td>p57 qPCR primers</td>
<td>S7</td>
<td></td>
</tr>
<tr>
<td>β-actin qPCR primers</td>
<td>S7</td>
<td></td>
</tr>
</tbody>
</table>

### Recombinant DNA

<table>
<thead>
<tr>
<th>DNA Description</th>
<th>Source</th>
<th>N/A</th>
</tr>
</thead>
<tbody>
<tr>
<td>WT PRMT6 and catalytically inactive PRMT6 mutant</td>
<td>Provided by Dr. Stéphane Richard (McGill University) (Neault et al., 2012)</td>
<td></td>
</tr>
</tbody>
</table>
CONTACT FOR REAGENTS AND RESOURCE SHARING

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Stephanie Ma (stefma@hku.hk).

EXPERIMENTAL MODEL AND SUBJECT DETAILS

Cell lines and organoid cultures
HCC cell lines SNU182 and HepG2 were purchased from American Type Culture Collect (ATCC). HCC cell lines PLC8024 and BEL7402 was obtained from Institute of Virology and Shanghai Institute of Cell Biology, respectively, of the Chinese Academy of Sciences, Beijing, China. HCC cell line, Huh7, was provided by JCRB Cell Bank (Japan). MHCC97L cells were obtained from Liver Cancer Institute, Fudan University, China. 293T and 293T/17 cells were purchased from ATCC; while 293FT was purchased from...
Invitrogen. Cell lines used in this study were regularly authenticated by morphological observation and tested for absence of Mycoplasma contamination. HCC and distal adjacent non-tumor liver tissues were obtained from patients undergoing hepatectomy or liver transplantation at Queen Mary Hospital, Hong Kong. Informed consent was obtained from all patients before the collection of liver specimens. Specimen collection and all experiments were approved by the Institutional Review Board of the University of Hong Kong / Hospital Authority Hong Kong West Cluster. Samples were collected from patients who had not received any previous local or systemic treatment prior to operation. For organoid cultures, cells were isolated and cultured according to previously reported protocol (Huch et al., 2015). Liver cells were isolated from human liver biopsies (0.5–1cm³) by collagenase-accutase digestion. The different fractions were mixed and washed with cold Advanced DMEM/F12 and spun at 300–400 × g for 5 min. The cell pellet was mixed with Matrigel (BD Biosciences) and 3,000–10,000 cells were seeded per well in a 24-well/plate. After Matrigel had solidified, culture medium was added. Culture media was based on AdDMEM/F12 (Invitrogen) supplemented with 1% N2 and 1% B27 (both from GIBCO), 1.25mM N-Acetylcysteine (Sigma), 10nM gastrin (Sigma), and the growth factors: 50ng/ml EGF (Peprotech), 25ng/ml HGF (Peprotech), 10mM Nicotinamide (Sigma), 5µM A83.01 (Tocris), and 10µM FSK (Tocris). For the establishment of the culture, the first 3 days after isolation, the medium was supplemented with 25ng/ml Noggin (Peprotech), 30% Wnt CM (homemade prepared), and 10µM Y27632, Sigma Aldrich). Then, the medium was changed into a medium without Noggin, Wnt or Y27632. After 10–14 days, organoids were removed from the Matrigel, mechanically dissociated into small fragments, and transferred to fresh matrix. Passage was performed in a 1:4–1:8 split ratio once every 7–10 days for at least 6 months. HCC and distant adjacent non-tumor liver tissues used for organoid established were also obtained from patients undergoing hepatectomy or liver transplantation at Queen Mary Hospital, Hong Kong, with informed consent obtained from all patients and protocol approved by ethics committee as stated above.

**Archived patient samples**

Formalin-fixed paraffin-embedded primary human HCC and adjacent non-tumor liver tissue samples were obtained from HCC patients who underwent surgical resection at the Sun Yat-Sen University Cancer Centre in Guangzhou, China. Informed consent was obtained from all patients before the collection of liver specimens. Specimen collection and all experiments were approved by the Institutional Review Board of Sun Yat-Sen University. Tissue samples were collected from patients who had not received any previous local or systemic treatment prior to operation.

**Animal studies**

The study protocol was approved by and performed in accordance with the Committee of the Use of Live Animals in Teaching and Research at The University of Hong Kong. PRMT6−/− mice were provided by Stéphane Richard (Neault et al., 2012). PRMT6−/− mice were viable, fertile and did not display any overt phenotype. WT C57BL/6J and PRMT6−/− mice were treated with N-nitrosodiethylamine (DEN, intraperitoneal, 1mg/kg) at the age of 14 days. Starting at 8 weeks of age, carbon tetrachloride (CCl₄, intraperitoneal, 0.2ml/kg) was administered twice weekly for an additional 14 weeks (Jehara et al., 2014). Body weight, liver weight, number and size of tumors were measured at end point. Livers were harvested for histological analysis. Tumorigenicity was determined by subcutaneous injection into the flank of 4-to-5 week old male BALB/C nude or NOD/SCID mice. Tumor-initiating and self-renewal abilities were investigated by limiting dilution and serial transplantation assays. 4-to-6 week old male NOD/SCID mice were injected subcutaneously with either 5,000 or 10,000 cells. Tumor incidence and tumor latency were recorded. Tumor-initiating frequency was calculated using the Extreme Limiting Dilution Analysis (ELDA) software. Established xenografts were harvested and dissociated for subsequence passage to secondary mouse recipients. After tumors were detected, tumor sizes were measured every 3 days by calipers and tumor volumes were calculated as volume (cm³) = L x W² x 0.5 with L and W representing the largest and smallest diameters, respectively. Tumors formed were harvested for histological analysis. Metastasis was assessed by orthotopically inject- ing into the liver of 6 week old BALB/C nude mice to observe for lung metastasis. Specifically, luciferase-labeled cells were injected into the left lobes of the livers of BALB/C nude mice. Six weeks after implantation, mice were administered with 100mg/kg D-luciferin via peritoneal injection 5 mins before biolumescent imaging (IVIS™ 100 Imaging System, Xenogen). Livers were harvested for ex vivo imaging and histological analysis. Animals that were injected with tumor cells but showed no sign of tumor burden were generally terminated six months after tumor cell inoculation, and animals were opened up at the injection sites to confirm that there was no tumor development.

**METHODS DETAILS**

**Reagents, kits and plasmids**

WT PRMT6 and catalytically inactive PRMT6 mutant (Neault et al., 2012) were provided by Stéphane Richard (McGill University, Canada). MEK inhibitor U0126 was purchased from Cell Signaling Technologies. ERK kinase assay was performed using the KinaseSTAR JNK assay kit (BioVision) where c-Jun was used as a substrate. CRAF kinase assay was purchased from Millpore (Upstate) where MEK1/2 was used as a substrate. WT and catalytically inactive PRMT6 were subcloned into Gateway entry vector pDONR201 (Invitrogen) using the forward primer 5’-GGGGACAAGTTTGTACAAAAAAGCAGGCTCCATTGCAGGCCAAGAAA GAAAGC-3’ and reverse primer 5’-GGGGACCACCTTTGACAAAGAGCTTGCTCCATTGCTCCCATGGCAGAAGCTTTG-3’. FL and
the truncated mutants of CRAF were cloned into Gateway vector pDONR201 by the following primers: FL: F (5'-GGGGACAGGTTTG TACAAAAGCGAGGCTCATGACAGAACATAGGAGCTTGGA-3'), R (5'-GGGGACACCTTTGTACAGAAAGCTGGGTCTCCTAG AGACAGGCAGCTCGGGGAC-3'); D1 (5'-GGGGACACTTTGTACAGAAGAGCTGGGTCTCCTAG AGACAGGCAGCTCGGGGAC-3'); D2 (5'-GGGGACACCTTTGTACAGAAAGCTGGGTCTCCTAG AGACAGGCAGCTCGGGGAC-3'); D3 (5'-GGGGACACCTTTGTACAGAAAGCTGGGTCTCCTAG AGACAGGCAGCTCGGGGAC-3'); D4 (5'-GGGGACACTTTGTACAGAAAGCTGGGTCTCCTAG AGACAGGCAGCTCGGGGAC-3'); D5 (5'-GGGGACACTTTGTACAGAAAGCTGGGTCTCCTAG AGACAGGCAGCTCGGGGAC-3'); D6 (5'-GGGGACACTTTGTACAGAAAGCTGGGTCTCCTAG AGACAGGCAGCTCGGGGAC-3'). PCR reactions were performed using the PrimeSTAR GXL kit (Takara). Gateway compatible plasmids including CMV-SFB, HA-FLAG and pMH-MBP were provided by Michael Huen (The University of Hong Kong, China). Recombination steps were accomplished with the use of Gateway and BP Clonase II and LR Clonase (Invitrogen). WT and catalytic inactive PRMT6 were shuttled into the EZShuttle recombination cloning expression vector pEZ-Lv199 (Genecopoeia) for lentiviral-based stable overexpression. RAS was subcloned into Gateway entry vector pDONR201 (Invitrogen) using forward primer 5'-GGGGACAGGTTTG TACAAAAGCGAGGCTCATGACAGAACATAGGAGCTTGGA-3' and reverse primer 5'-GGGGACACCTTTGTACAGAAAGCTGGGTCTCCTAG AGACAGGCAGCTCGGGGAC-3' and subsequently shuttled into pMH-MBP. The site-directed mutants of CRAF were constructed using the primers: R89K F (5'-CTCAAGG TGAAGGAGCTCGA-3'), R (5'-TTGCAAGGCTCTCCACCTTTGAG-3') and R100K F (5'-GCAGTTGTTCAACTCTCACCCAC-3', R (5'-GTGGAGAAAGTGGGACACACTTG-3') such that arginine-to-lysine conversions were introduced. For in vitro methylation assay, WT and site-directed mutants were subcloned into glutathione S-transferase (GST)-tag containing pGEX4t1 vector (Addgene). All DNA expression constructs were confirmed by DNA sequencing.

Flow cytometry and cell sorting
Flow cytometry analysis or flow cytometry cell sorting was conducted using PE-conjugated mouse anti-human CD133 (Miltenyi Biotec), FITC-conjugated mouse anti-human CD24 (BD Biosciences), FITC-conjugated mouse anti-human CD90 (Miltenyi Biotec) and its respective isotype control. Samples were analyzed and sorted on BD FACSCanto II and FACSAria I, respectively (BD Biotec), FITC-conjugated mouse anti-human CD133 (Miltenyi Biotec), FITC-conjugated mouse anti-human CD90 (Miltenyi Biotec) and its respective isotype control. Samples were analyzed and sorted on BD FACSCanto II and FACSAria I, respectively (BD Biosciences) with data analyzed by FlowJo (Tree Star Inc.).

Gene expression profiling
Gene expression profiling studies involving non-tumor liver (n = 50) and HCC (n = 371) tissue samples were performed analyzing the expression of PRMT6 transcripts available under Liver Hepatocellular Carcinoma (LIHC) of the TCGA Research Network and analyzed using UCSC Xena Browser.

Agilent microarray profiling
cDNA microarray profiling on Agilent Human Gene Expression Array 8x60K v3 was performed as a service at Macrogen. Pathway enrichment analyses on the differentially expressed genes were conducted using Gene Set Enrichment Analysis (GSEA, Broad Institute) and its respective isotype control. Samples were analyzed and sorted on BD FACSCanto II and FACSAria I, respectively (BD Biosciences) with data analyzed by FlowJo (Tree Star Inc.).

Quantitative real-time PCR
Total RNA was extracted using RNA-Isolus (Takara) and cDNA was synthesized by PrimeScript RT Master Mix (Takara). qPCR was performed with EvaGreen qPCR Master Mix (ABM) and the following primers PRMT6: F (5' - ACGAGGTGCTACTCGGAGGTT-3'), R (5' - AGTCTCAAGGATCCACCAGGAG-3') and β-ACTIN: F (5' - CTACAGCAGGACTACCTCATACTC-3'), R (5' - GACCGGCGGATCACAGCAGC-3') on an ABI Prism 7900 System (Applied Biosystems) with data analyzed using the ABI SDS v2.3 software (Applied Biosystems). Relative expression differences were calculated using the 2−ΔΔCt method.

Western blot and co-immunoprecipitation
Protein lysates were quantified and resolved on a SDS-PAGE gel, transferred onto a PVDF membrane (Millipore) and immunoblotted with a primary antibody, followed by incubation with a secondary antibody. Antibody signal was detected using an enhanced chemiluminescence system (GE Healthcare). The following antibodies were used: PRMT6 (1:500, Abcam, ab47244) (Phalke et al., 2012), CD133 (1:500, Miltenyi Biotec, 130-092-395), AMDA (1:1000, Cell Signaling, 13522), SOX2 (1:1000, Abcam, ab97959), NANO (1:1000, Cell Signaling), H3R2me2a (1:1000, Millipore, 07-585), FLAG (1:5000, Sigma-Aldrich, F3165), p-CRAF (S338) (1:1000, Cell Signaling), CRAF (1:1000, Cell Signaling, 12552), ARAF (1:1000, Cell Signaling, 4432), BRAF (1:1000, Cell Signaling, 12552), p-ERK1/2 (1:1000, Cell Signaling, 9101), ERK1/2 (1:1000, Cell Signaling, 9102), p-MEK1/2 (S127/221) (1:1000, Cell Signaling, 9154), MEK1/2 (1:1000, Cell Signaling, 9122), RAS (1:500, Calbiochem, OP01L), Histone H3 (1:1000, Abcam, ab24834), p53 (1:1000, Cell Signaling, 9282) and β-ACTIN (1:5000, Sigma-Aldrich, A5316). For Co-IP experiments, cells were lysed by ice-cold NETN buffer (20mM Tris-HCl pH 8.0, 100mM NaCl, 1mM EDTA and 0.5% v/v NP40), and the SFB- or HA-FLAG-tagged proteins were pulled-down by streptavidin bead slurry (Amersham) and anti-FLAG M2 affinity gel (Sigma-Aldrich), respectively. The proteins were precipitated by incubation under 4°C for 3-4 hr with gentle shaking. For endogenous PRMT6 Co-IP experiments, cells were lysed by ice-cold NETN buffer and endogenous PRMT6 was pulled-down by PRMT6 antibody (5 µg/mg lysate, Bethyl Laboratories, A300-928A) and Protein A Sepharose (BioVision). The proteins were precipitated by incubation under 4°C for 16 hr.
with gentle shaking. Rabbit IgG (Santa Cruz, sc-2027) was used as control. The protein was eluted by heating at 95°C for 5 mins and mixed with 6x loading buffer for SDS-PAGE and western blot analyses.

**Lentiviral production and cell transduction**

PRMT6-specific shRNA expression vectors (NM_018137.2) and the scrambled shRNA non-target control (NTC) were purchased from Sigma-Aldrich. Sequences of the two shRNAs directed against PRMT6 are as follows: clone ID TRCN0000299933 (CCCGACGCCAATTTGGGGGAATCGATCTCCTGCAAGATGGCAGTGTGTGGTGTGGTTTTTG) and clone ID TRCN0000299556 (CCCGACGCCAATTTGGGGGAATCGATCTCCTGCAAGATGGCAGTGTGTGGTGTGGTTTTTG). Sequences directed against ERK1 and ERK2 are as follow: (CCGCGTATACCAAGTCCATCGACATCTCGAGATGTCGATGGACTTGGTATAGTTTTTG) and (CCGGACATTATCGAGCACCAACCCTCGAGGGTTGGTGCTCGAATAATGCTCGGGTGTGGTGTGGTTTTTG), respectively. Sequence of NTC is (CCGGCAACAAGATGGAAGAGCACAACTCGAGTTGGTGCTCTTCATCTTGTTT). Sequences were transfected into 293FT cells and packaged using MISSION Lentiviral Packaging Mix (Sigma-Aldrich). PRMT6 lentiviral overexpression or empty vector control plasmids were purchased from Genecopoeia or Viral Power packaging mix (Invitrogen). Virus-containing supernatants were collected for subsequent transduction to establish cells with PRMT6 stably repressed or overexpressed. Puromycin or blasticidin were used for cell selection. For transduction of organoids, the same overexpression and knockdown vectors were transfected into 293T/17 cells with PEI. Virus-containing supernatant was passed through a 0.45μm filter and ultracentrifuged at 15,000 g for 2 hr. Organoids were first dissociated into single cells prior to infection with the lentivirus and then selected with puromycin, as previously described (Huch et al., 2015).

**CRISPR/Cas9 knockout**

The gRNA-coding cDNAs for human PRMT6 gene were designed and synthesized to make the lentiviral PRMT6-gRNA-Cas9 constructs. Briefly, the 24bp forward and reverse primers including 20bp target sequence and BsmBI sticky end were annealed and inserted into the lentiCRISPR-v2 plasmid (Addgene 52961) digested with BsmBI (Fermentas). Primer sequences are as follows: KO#1, forward, 5’-CACCCTGGTGGCGTGGTACCAAAAGT-3’ and reverse, 5’-AAACACTTTGTAGCCGACGACAC-3’; KO#2, forward, 5’-CACCCTGGTGGCGTGGTACCAAAAGT-3’ and reverse, 5’-AAACACTTTGTAGCCGACGACAC-3’. Sequences (0.5 μg) were transfected into 293T cells and packaged using 1 μg pMDL + 1 μg pRSV + 1 μg pVSVG (Addgene). Virus-containing supernatants were collected for subsequent transduction to establish cells with PRMT6 knocked out. Puromycin was used for cell selection.

**Immunohistochemistry**

Slides were heated for antigen retrieval in 10mM sodium citrate (pH 6.0). Endogenous peroxidase activity was inhibited with 3% hydrogen peroxide. Sections were subsequently incubated with anti-human/mouse PRMT6 (1:1000 for human, 1:100 for mouse, Abcam, ab47244), anti-human PRMT6 (1:300, Atlas Antibodies, HPA059424), anti-mouse SOX2 (1:100, R&D Systems, MAB2018) and anti-mouse p-ERK1/2 (1:100, Abcam, ab50011). Reaction was developed with DAB+ Substrate-Chromogen System (Dako). Slides were counterstained with Mayer’s hematoxylin.

**Immunofluorescence**

Cells were fixed with 4% paraformaldehyde, permeabilized with 0.1% Triton X (Sigma-Aldrich), blocked with normal goat serum and incubated with anti-human PRMT6 (1:1000, Abcam, ab47244) or anti-human PRMT6 (1:1000, Atlas Antibodies, HPA059424), followed by Alexa Fluor conjugated secondary antibody. Cells were counterstained with anti-fade DAPI (Invitrogen) and visualized by fluorescent confocal microscope (Carl Zeiss LSM 700).

**Oncosphere-forming and self-renewal assay**

Single cells were cultured in 300μl of serum-free DMEM/F12 medium (Invitrogen) supplemented with 20ng/ml human recombinant epidermal growth factor (Sigma-Aldrich), 10ng/ml human recombinant basic fibroblast growth factor (Sigma-Aldrich), 4μg/ml insulin (Sigma-Aldrich), B27 (1:50; Invitrogen), 500U/ml penicillin, 500μg/ml streptomycin (Invitrogen) and 1% methylcellulose (Sigma-Aldrich). Cells were cultured in suspension in poly-HEMA-coated 24-well plates. Cells were replenished with 30μl of supplemented medium every second day. To propagate spheres in vitro, spheres were collected by gentle centrifugation and dissociated to single cells using TrypLE Express (Invitrogen). Following dissociation, trypsin inhibitor (Invitrogen) was used to neutralize the reaction, and the cells were cultured to generate the next generation of spheres.

**Cell motility and invasion assays**

Migration and invasion assays were conducted in 24-well Millicell hanging inserts (Millipore) and 24-well BioCoat Matrigel Invasion Chambers (BD Biosciences), respectively. Cells re-suspended in serum free DMEM were added to the top chamber and medium supplemented with 10% FBS was added to the bottom chamber as a chemoattractant. After 48 hr of incubation at 37°C, cells that migrated or invaded through the membrane (migration) or Matrigel (invasion) were fixed and stained with crystal violet (Sigma-Aldrich). The number of cells was counted in 3 random fields under 20x objective lens and imaged using SPOT imaging software (Nikon).
Affinity purification of PRMT6 protein complexes was carried out as described previously (Feng et al., 2016) on whole cell lysates. Stable clones of 293T cells expressing PRMT6 with C-terminally tagged with SFB were harvested and lysed in NETN buffer for 30 mins on ice. After removal of cell debris by centrifugation at 14k rpm for 15 mins, supernatant containing PRMT6-protein complexes was first immunoprecipitated by streptavidin bead slurry (Amersham) for 4 hr at 4°C. The precipitated protein complexes were then eluted by incubation with NETN buffer containing 2mg/ml biotin (Sigma-Aldrich). The biotin-eluare was then incubated with S protein agarose (Novagen) for 3 hr to perform a second round of immunoprecipitation. The protein complexes were eluted by heating at 95°C for 5 mins. The eluate was subjected to mass spectrometric analysis (LC/MS/MS) at Taplin Mass Spectrometry Facility (Harvard).

Methylation assays
For in vivo methylation, 293T cells were co-transfected with HA-FLAG-CRAF and PRMT6 plasmids. 48 hr later, the cells were lysed by NETN buffer and immunoprecipitation was performed to pull down the HA-FLAG-tagged CRAF protein. The input and eluted protein lysates were resolved by SDS-PAGE and analyzed by western blotting. The level of asymmetric dimethylated arginine in HA-FLAG-PRMT6 or CVM-SFB was mixed with 1 μg of GST-CRAF in the presence of 1 μCi of [methyl-3H] S-adenosyl-L-methionine (Amersham) and 25mM Tris-HCl (pH 7.5) for 2 hr at 30°C in a final volume of 50μl. Reactions were stopped by adding 20μl of 2x Laemmli buffer, followed by heating at 100°C for 5 mins. Products were loaded into SDS-PAGE and analyzed by western blotting. The radioactive signals from GST-CRAF were visualized by fluorography with En3Hance (Perkin-Elmer) according to manufacturer’s instructions. For in vitro peptidemethylation, SFB-PRMT6 protein was immunoprecipitated from crude extract of 293T stable clones. 293T-CMV-SFB stable cells were used as control. The substrate GST-CRAF was purified from transformed BL21 competent E. coli. Quantity of input lysates for IP was normalized by measurement of protein concentration and also by SDS-PAGE and subsequent Coomassie blue staining. Equal amount of immobilized SFB-PRMT6 or CVM-SFB was mixed with 1 μg of GST-CRAF in the presence of 1 μCi of [methyl-3H] S-adenosyl-L-methionine (Amersham) and 25mM Tris-HCl (pH 7.5) for 2 hr at 30°C in a final volume of 50μl. Reactions were stopped by adding 20μl of 2x Laemmli buffer, followed by heating at 100°C for 5 mins. Products were loaded into SDS-PAGE and analyzed by western blotting. The radioactive signals from GST-CRAF were visualized by fluorography with En3Hance (Perkin-Elmer) according to manufacturer’s instructions.

Liquid chromatography–mass spectrometry analysis
SBF-PRMT6 was incubated with 100 μg of CRAF R100 peptide in the presence of 500ng S-(5′-Adenosyl)-L-methionine chloride dihydrochloride (Sigma-Aldrich) for 2 hr at 30°C in a final volume of 50 μL methylation buffer. The reaction supernatant was analyzed by liquid chromatography-mass spectrometry and mass spectrometry (LC-MS/MS) on Orbitrap Fusion Lumos Tribid Mass Spectrometer (Thermo Scientific) at the Proteomics & Metabolomics Core Facility, The University of Hong Kong. Data analysis was performed using PEAKS DB software (Bioinformatics Solutions Ltd).

In vitro RAS binding assay
For RAS preparation, MBP-RAS was purified from transformed BL21 competent E. coli, and loaded with 0.1M GTP. For in vitro methylation and sequential RAS binding assay, equal amount of GST-CRAF or GST-CRAF-R100K was incubated with immobilized SFB-PRMT6 and 1 μCi of [methyl-3H] S-adenosyl-L-methionine (Amersham) at for 2 hr at 30°C in a final volume of 50 μL methylation buffer. The reaction supernatant was then incubated with MBP-RAS-GTPYS and Glutathione Sepharose for 2 hr at 4°C. After washing the beads, the reaction products were analyzed by western blotting.

ChIP-qPCR
ChIP was performed with the Magna ChIP G – Chromatin Immunoprecipitation Kit (Millipore) according to manufacturer’s instructions. Briefly, cells were crosslinked in the presence of 1% formaldehyde at room temperature for 10 min and harvested after washing with cold PBS. Immunoprecipitation of crosslinked protein/DNA was carried out with 4 μg of anti-histone H3 (asymmetric di

Annexin V apoptosis assay
Cells were treated with various concentrations of chemo and molecular targeted therapeutic drugs, 5-fluorouracil, cisplatin and sorafenib for 4 days. Cell viability was measured by CellTiter-Glo assay (Promega) with data presented as percentage of viability relative to blank or vehicle control.

Cell viability assay
Organoids were treated with various concentrations of chemo and molecular targeted therapeutic drugs, 5-fluorouracil, cisplatin and sorafenib for 4 days. Cell viability was measured by CellTiter-Glo assay (Promega) with data presented as percentage of viability relative to blank or vehicle control.
methyl R2) antibody (Abcam, ab175007) or rabbit IgG control (Santa Cruz, sc-2027). Immunoprecipitated and eluted DNA was purified with columns and amplified by qPCR with the following primers: p21 promoter region, forward, 5′-TGCCTCA CAGGTGTTTCTG-3′ and reverse, 5′-CACATCCCCGACTCTCGTCA-3′; p27 promoter region, forward, 5′-ACTCGCCGCTGTCAAT CATT-3′ and reverse, 5′-AACACCCCCGAAGACAG-3′; p57 promoter region, forward, 5′-TCCAGCTCAGCTTTTG-3′ and reverse, 5′- TCCAGTCTGTTTGCTTG-3′.

QUANTIFICATION AND STATISTICAL ANALYSIS

Statistical analyses were performed using GraphPad Prism 5.0 and SPSS 21.0. Independent Student’s t test was used to compare the mean value of two groups. Clinico-pathological significance in clinical samples was evaluated by Fisher’s exact test and independent Student’s t test for categorical data and continuous data, respectively. The differences in survival were calculated using the Kaplan-Meier test. Survival analysis in mouse model was performed by log-rank test. Data representative of two or more independent experiments. Bars and error represent mean ± standard deviations (SD) of replicate measurements. Statistical significance was defined as \( p \leq 0.05 \). \( ^*p < 0.05 \), \( ^{**}p < 0.01 \) and \( ^{***}p < 0.001 \). Number of animals included per group can be found in each respective Figure.

DATA AND SOFTWARE AVAILABILITY

Microarray gene expression data are deposited at the NCBI GEO under the accession number GEO: GSE97931.